SIRT5 inhibitors and degraders as novel treatments for Ewing sarcoma

SIRT5 抑制剂和降解剂作为尤文肉瘤的新型治疗方法

基本信息

项目摘要

Abstract Ewing sarcoma (EWS) is an aggressive tumor arising in soft tissue and bone of children and young adults. EWS is treated with a combination of cytotoxic chemotherapy, local radiation, and/or surgery. Patients with localized disease show a favorable overall survival rate. However, there is still a pressing need for new therapeutic approaches for EWS. Patients with metastatic or recurrent EWS have a very poor prognosis. Moreover, current EWS treatments are associated with many short- and long-term sequelae, e.g. accelerated cardiovascular disease and secondary cancers. EWS-FLI1 is the fusion oncoprotein present in most cases of EWS. It functions as a pioneer transcription factor to affect expression of many target genes. The aberrant EWS transcriptome represents a potential therapeutic target in EWS. This proposal focuses on the sirtuin SIRT5 as a novel therapeutic target in EWS. SIRT5 is found throughout the cell, and regulates protein targets in diverse pathways by removing negatively charged modifications on lysine residues, including succinylation. Although normal cell types and whole mice tolerate loss of SIRT5 with minimal phenotypes, we have found that specific cancers, notably including EWS, are exquisitely dependent on SIRT5, and rapidly undergo apoptosis following SIRT5 depletion. We have linked this effect to a role for SIRT5 in desuccinylating nuclear histones, thereby modulating gene expression in EWS. We and others have shown that SIRT5 is in principle amenable to selective inhibition or degradation with small molecules. Our long-term goal is to evaluate SIRT5 as a potential therapeutic target for EWS. The objective of this proposal is to generate new biological insights into SIRT5 function in EWS, and characterize SIRT5 inhibitors and SIRT5 PROTAC-based degraders. The central hypotheses of this application are that: 1) SIRT5 is required for EWS cell survival via histone desuccinylation and regulation of gene expression; and 2) SIRT5 inhibitors and degraders will represent useful tool compounds to interrogate SIRT5 biology, and a starting point for potential future EWS therapeutics. The rationale for this application is that EWS cells show exquisite vulnerability to SIRT5 loss-of-function, while other cell types and whole mice show no major ill effects. Hence, SIRT5 inhibition would likely be well tolerated clinically. The work will take place in the context of two Specific Aims. First, we will elucidate the impact of SIRT5 and Ksucc on histones and gene expression, using mass spectrometry along with transcriptomic and epigenomic approaches. Second, we will optimize and validate SIRT5 inhibitors and degraders, using medicinal chemistry approaches and based in part on SIRT5-inhibitor co-crystal structures. The application is innovative, in that no published data currently link SIRT5 to EWS, and no potent and selective SIRT5 inhibitors or PROTACs have as yet been described. The work is significant, since there is an unmet clinical need for improved therapies for EWS.
摘要 尤文肉瘤是一种发生于儿童和青少年软组织和骨骼的侵袭性肿瘤 成年人了EWS用细胞毒性化疗、局部放射和/或手术的组合治疗。 局限性疾病患者的总体生存率较好。然而,仍然有一个紧迫的 EWS需要新的治疗方法。转移性或复发性EWS的患者 预后不良。此外,目前的EWS治疗与许多短期和长期的 后遗症,例如加速的心血管疾病和继发性癌症。EWS-FLI 1是融合 癌蛋白存在于大多数EWS病例中。它作为一个先锋转录因子影响 许多靶基因的表达。异常的EWS转录组代表了一种潜在的治疗方法, 目标在EWS。该提案的重点是sirtuin SIRT 5作为EWS的新治疗靶点。SIRT5 在整个细胞中发现,并通过去除负性蛋白质来调节不同途径中的蛋白质靶点。 赖氨酸残基上的带电修饰,包括琥珀酰化。虽然正常的细胞类型和整个 小鼠耐受SIRT 5的损失,具有最小的表型,我们发现特定的癌症,特别是 包括EWS在内的细胞都非常依赖SIRT 5,并在SIRT 5后迅速发生凋亡。 耗尽我们已经将这种效应与SIRT 5在去琥珀酰化核组蛋白中的作用联系起来, 调节EWS中的基因表达。我们和其他人已经表明,SIRT 5原则上是适合的, 用小分子选择性抑制或降解。我们的长期目标是评估SIRT 5作为一种 EWS的潜在治疗靶点。这项提案的目的是产生新的生物学见解 研究SIRT 5在EWS中功能,并表征SIRT 5抑制剂和基于SIRT 5 PROTAC的降解剂。 本申请的中心假设是:1)SIRT 5是EWS细胞存活所需的,通过组蛋白 去琥珀酰化和基因表达的调节;和2)SIRT 5抑制剂和降解剂将代表 询问SIRT 5生物学的有用工具化合物,以及潜在未来EWS的起点 治疗学这种应用的基本原理是,EWS细胞对SIRT 5表现出极其脆弱的脆弱性。 功能丧失,而其他细胞类型和整个小鼠没有显示出重大的不良影响。因此,SIRT 5抑制 在临床上可能耐受良好。这项工作将在两个具体目标的背景下进行。第一、 我们将利用质量来阐明SIRT 5和Ksucc对组蛋白和基因表达的影响 光谱法沿着转录组学和表观基因组学方法。第二,我们将优化和 验证SIRT 5抑制剂和降解剂,使用药物化学方法,部分基于 SIRT 5-抑制剂共晶体结构。该应用程序是创新的,因为目前没有公布的数据 将SIRT 5与EWS联系起来,目前还没有有效的选择性SIRT 5抑制剂或PROTAC。 介绍了这项工作是重要的,因为有一个未满足的临床需要,改善治疗EWS。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

David Benner Lombard其他文献

David Benner Lombard的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('David Benner Lombard', 18)}}的其他基金

SIRT5 inhibitors and degraders as novel treatments for Ewing sarcoma
SIRT5 抑制剂和降解剂作为尤文肉瘤的新型治疗方法
  • 批准号:
    10385995
  • 财政年份:
    2022
  • 资助金额:
    $ 51.83万
  • 项目类别:
Targeting the longevity regulator PAPP-A with small molecule inhibitors
使用小分子抑制剂靶向寿命调节剂 PAPP-A
  • 批准号:
    10464342
  • 财政年份:
    2022
  • 资助金额:
    $ 51.83万
  • 项目类别:
Targeting the longevity regulator PAPP-A with small molecule inhibitors
使用小分子抑制剂靶向寿命调节剂 PAPP-A
  • 批准号:
    10668304
  • 财政年份:
    2022
  • 资助金额:
    $ 51.83万
  • 项目类别:
Elucidating epigenetic mechanisms of cellular cadmium toxicity
阐明细胞镉毒性的表观遗传机制
  • 批准号:
    10669969
  • 财政年份:
    2022
  • 资助金额:
    $ 51.83万
  • 项目类别:
Elucidating epigenetic mechanisms of cellular cadmium toxicity
阐明细胞镉毒性的表观遗传机制
  • 批准号:
    10266094
  • 财政年份:
    2020
  • 资助金额:
    $ 51.83万
  • 项目类别:
Mechanisms of age-associated cardiac heterochromatin dysfunction
年龄相关心脏异染色质功能障碍的机制
  • 批准号:
    9165389
  • 财政年份:
    2016
  • 资助金额:
    $ 51.83万
  • 项目类别:
Mechanisms of tumor suppression by the chromatin deacetylase SIRT6
染色质脱乙酰酶 SIRT6 抑制肿瘤的机制
  • 批准号:
    8689985
  • 财政年份:
    2013
  • 资助金额:
    $ 51.83万
  • 项目类别:
Mechanisms of tumor suppression by the chromatin deacetylase SIRT6
染色质脱乙酰酶 SIRT6 抑制肿瘤的机制
  • 批准号:
    8564971
  • 财政年份:
    2013
  • 资助金额:
    $ 51.83万
  • 项目类别:
Regulation of one carbon metabolism and epigenetics by SIRT5
SIRT5 对一碳代谢和表观遗传学的调节
  • 批准号:
    9922907
  • 财政年份:
    2012
  • 资助金额:
    $ 51.83万
  • 项目类别:
Autophagy regulation of RSV-induced pulmonary disease
RSV 诱导的肺部疾病的自噬调节
  • 批准号:
    9178093
  • 财政年份:
    2012
  • 资助金额:
    $ 51.83万
  • 项目类别:

相似海外基金

SHINE: Origin and Evolution of Compressible Fluctuations in the Solar Wind and Their Role in Solar Wind Heating and Acceleration
SHINE:太阳风可压缩脉动的起源和演化及其在太阳风加热和加速中的作用
  • 批准号:
    2400967
  • 财政年份:
    2024
  • 资助金额:
    $ 51.83万
  • 项目类别:
    Standard Grant
Collaborative Research: FuSe: R3AP: Retunable, Reconfigurable, Racetrack-Memory Acceleration Platform
合作研究:FuSe:R3AP:可重调、可重新配置、赛道内存加速平台
  • 批准号:
    2328975
  • 财政年份:
    2024
  • 资助金额:
    $ 51.83万
  • 项目类别:
    Continuing Grant
EXCESS: The role of excess topography and peak ground acceleration on earthquake-preconditioning of landslides
过量:过量地形和峰值地面加速度对滑坡地震预处理的作用
  • 批准号:
    NE/Y000080/1
  • 财政年份:
    2024
  • 资助金额:
    $ 51.83万
  • 项目类别:
    Research Grant
Market Entry Acceleration of the Murb Wind Turbine into Remote Telecoms Power
默布风力涡轮机加速进入远程电信电力市场
  • 批准号:
    10112700
  • 财政年份:
    2024
  • 资助金额:
    $ 51.83万
  • 项目类别:
    Collaborative R&D
Collaborative Research: FuSe: R3AP: Retunable, Reconfigurable, Racetrack-Memory Acceleration Platform
合作研究:FuSe:R3AP:可重调、可重新配置、赛道内存加速平台
  • 批准号:
    2328973
  • 财政年份:
    2024
  • 资助金额:
    $ 51.83万
  • 项目类别:
    Continuing Grant
Collaborative Research: FuSe: R3AP: Retunable, Reconfigurable, Racetrack-Memory Acceleration Platform
合作研究:FuSe:R3AP:可重调、可重新配置、赛道内存加速平台
  • 批准号:
    2328972
  • 财政年份:
    2024
  • 资助金额:
    $ 51.83万
  • 项目类别:
    Continuing Grant
Collaborative Research: A new understanding of droplet breakup: hydrodynamic instability under complex acceleration
合作研究:对液滴破碎的新认识:复杂加速下的流体动力学不稳定性
  • 批准号:
    2332916
  • 财政年份:
    2024
  • 资助金额:
    $ 51.83万
  • 项目类别:
    Standard Grant
Collaborative Research: A new understanding of droplet breakup: hydrodynamic instability under complex acceleration
合作研究:对液滴破碎的新认识:复杂加速下的流体动力学不稳定性
  • 批准号:
    2332917
  • 财政年份:
    2024
  • 资助金额:
    $ 51.83万
  • 项目类别:
    Standard Grant
Collaborative Research: FuSe: R3AP: Retunable, Reconfigurable, Racetrack-Memory Acceleration Platform
合作研究:FuSe:R3AP:可重调、可重新配置、赛道内存加速平台
  • 批准号:
    2328974
  • 财政年份:
    2024
  • 资助金额:
    $ 51.83万
  • 项目类别:
    Continuing Grant
Radiation GRMHD with Non-Thermal Particle Acceleration: Next-Generation Models of Black Hole Accretion Flows and Jets
具有非热粒子加速的辐射 GRMHD:黑洞吸积流和喷流的下一代模型
  • 批准号:
    2307983
  • 财政年份:
    2023
  • 资助金额:
    $ 51.83万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了